D. E. Shaw & Co. Inc. lessened its stake in shares of Glaukos Corp (NYSE:GKOS) by 64.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 94,938 shares of the medical instruments supplier’s stock after selling 169,799 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.27% of Glaukos worth $5,333,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Oppenheimer Asset Management Inc. acquired a new stake in shares of Glaukos during the fourth quarter worth about $31,000. NumerixS Investment Technologies Inc lifted its position in shares of Glaukos by 20.7% during the fourth quarter. NumerixS Investment Technologies Inc now owns 1,100 shares of the medical instruments supplier’s stock worth $61,000 after purchasing an additional 189 shares in the last quarter. Rehmann Capital Advisory Group acquired a new stake in Glaukos in the third quarter valued at approximately $63,000. Strs Ohio acquired a new stake in Glaukos in the fourth quarter valued at approximately $78,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Glaukos by 24.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,583 shares of the medical instruments supplier’s stock valued at $145,000 after acquiring an additional 508 shares in the last quarter.
GKOS stock opened at $76.65 on Friday. Glaukos Corp has a twelve month low of $26.75 and a twelve month high of $83.14.
Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, February 27th. The medical instruments supplier reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.17. Glaukos had a negative net margin of 7.14% and a negative return on equity of 8.24%. The company had revenue of $54.08 million for the quarter, compared to analysts’ expectations of $49.60 million. During the same quarter last year, the company earned $0.03 earnings per share. The firm’s revenue for the quarter was up 29.8% on a year-over-year basis. On average, equities research analysts expect that Glaukos Corp will post -0.33 earnings per share for the current year.
GKOS has been the topic of several analyst reports. Wells Fargo & Co reaffirmed a “buy” rating on shares of Glaukos in a report on Wednesday, March 20th. Zacks Investment Research raised shares of Glaukos from a “sell” rating to a “hold” rating and set a $74.00 target price on the stock in a report on Monday, March 4th. BTIG Research initiated coverage on shares of Glaukos in a report on Friday, March 8th. They issued a “neutral” rating and a $66.02 target price on the stock. Stephens raised their target price on shares of Glaukos from $70.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, February 28th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $80.00 target price on shares of Glaukos in a report on Thursday, February 28th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $71.34.
In other news, CFO Joseph E. Gilliam sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $70.03, for a total transaction of $350,150.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Chris M. Calcaterra sold 90,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $67.69, for a total transaction of $6,092,100.00. Following the transaction, the chief operating officer now owns 193,344 shares in the company, valued at $13,087,455.36. The disclosure for this sale can be found here. 11.60% of the stock is currently owned by company insiders.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.
Further Reading: Reverse Stock Split
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.